Cargando…

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study

The objective of this study is to describe the characteristics and outcomes of rheumatic and musculoskeletal disease (RMD) patients who were treated with rituximab and had suspected or confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this descriptive study, RMD pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loarce-Martos, Jesús, García-Fernández, Antía, López-Gutiérrez, Fernando, García-García, Verónica, Calvo-Sanz, Laura, del Bosque-Granero, Iván, Terán-Tinedo, M. Andreína, Boteanu, Alina, Bachiller-Corral, Javier, Vázquez-Díaz, Mónica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Observational Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499013/ https://www.ncbi.nlm.nih.gov/pubmed/32945944 http://dx.doi.org/10.1007/s00296-020-04699-x

Ejemplares similares

Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases
por: Clemente, Daniel, et al.
Publicado: (2021)

Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study
por: Wade, Stefanie D., et al.
Publicado: (2021)

Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study
por: Esquivel-Valerio, Jorge Antonio, et al.
Publicado: (2021)

The COVID-19 epidemic curve and vaccine acceptance among patients with rheumatic diseases: an ecological study
por: Gastelum-Strozzi, Alfonso, et al.
Publicado: (2023)

Current perspective on rituximab in rheumatic diseases
por: Schioppo, Tommaso, et al.
Publicado: (2017)

Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience
por: Migkos, Michalis P., et al.
Publicado: (2021)

Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases
por: Alzahrani, Zeyad A., et al.
Publicado: (2021)

Impact of the COVID-19 pandemic on the frequency of the pediatric rheumatic diseases
por: Kaya Akca, Ummusen, et al.
Publicado: (2021)

Impact of COVID-19 pandemic on patients with rheumatic diseases in Latin America
por: Fernández-Ávila, Daniel G., et al.
Publicado: (2021)

YouTube as a source of information on COVID-19 vaccination in rheumatic diseases
por: Kocyigit, Burhan Fatih, et al.
Publicado: (2021)

Psychosocial and clinical effects of the COVID-19 pandemic in patients with childhood rheumatic diseases and their parents
por: Durcan, Gizem, et al.
Publicado: (2021)

A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease
por: Cronin, Owen, et al.
Publicado: (2021)

COVID-19 vaccine hesitancy in patients with systemic autoimmune rheumatic disease: an interview-based survey
por: Gaur, Priyanka, et al.
Publicado: (2021)

Effects of the second dose of COVID-19 vaccines in patients with autoimmune rheumatic diseases with hybrid immunity
por: Menon, Aparna R., et al.
Publicado: (2022)

Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab
por: Łosińska, Katarzyna, et al.
Publicado: (2023)

The impact of the ongoing COVID-19 pandemic on the management of rheumatic disease: a national clinician-based survey
por: Kahveci, Abdulvahap, et al.
Publicado: (2022)

Telemedicine for patients with rheumatic and musculoskeletal diseases during the COVID-19 pandemic; a positive experience in the Netherlands
por: Bos, Wouter H., et al.
Publicado: (2021)

How to optimize recruitment strategies of patients with rheumatic and musculoskeletal diseases for online surveys: experience from an international study
por: Hmamouchi, Ihsane, et al.
Publicado: (2022)

Public interest in rheumatic diseases and rheumatologist in the United States during the COVID-19 pandemic: evidence from Google Trends
por: Kardeş, Sinan, et al.
Publicado: (2020)

Isolation in patients with inflammatory rheumatic diseases during COVID-19 pandemic compared to healthy individuals: a questionnaire survey
por: Eriksen, Tobias Eschricht, et al.
Publicado: (2022)

Correlates of breakthrough Omicron (B.1.1.529) infections in a prospective cohort of vaccinated patients with rheumatic diseases
por: Benny, Libin, et al.
Publicado: (2023)

The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey
por: Seyahi, Emire, et al.
Publicado: (2020)

Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19
por: Koker, Oya, et al.
Publicado: (2020)

Increased influenza vaccination rates in patients with autoimmune rheumatic diseases during the Covid-19 pandemic: a cross-sectional study
por: Fragoulis, George E., et al.
Publicado: (2021)

COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study
por: Fragoulis, George E., et al.
Publicado: (2021)

Patients with rheumatic diseases are ready to use social media in clinical practice; what about rheumatologists? A cross-sectional survey
por: Erdogan, M., et al.
Publicado: (2021)

Management of chronic rheumatic diseases in women 18–45 years of age in Asia Pacific: insights from patient and clinician surveys
por: Tanaka, Yoshiya, et al.
Publicado: (2022)

A survey of Canadian adult rheumatologists’ knowledge, comfort level, and barriers in assessing psychosocial needs of young adults with rheumatic diseases
por: Prasad, Madhavi, et al.
Publicado: (2023)

The role of dermoscopy and digital dermoscopy follow-up in the clinical diagnosis of melanoma: clinical and dermoscopic features of 99 consecutive primary melanomas
por: Salerni, Gabriel, et al.
Publicado: (2014)

Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey
por: Yurttas, Berna, et al.
Publicado: (2021)

The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study
por: Sozeri, Betul, et al.
Publicado: (2021)

Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant
por: Chihara, Dai, et al.
Publicado: (2021)

Diagnostic delay stages and pre-diagnostic treatment in patients with suspected rheumatic diseases before special care consultation: results of a multicenter-based study
por: Fuchs, Franziska, et al.
Publicado: (2022)

Higher rate of progression in HIV(–) than in HIV(+) patients after rituximab for HHV8(+) multicentric Castleman disease
por: Rasmussen, Camille, et al.
Publicado: (2023)

Reclassifying Pseudopolyps in Inflammatory Bowel Disease: Histologic and Endoscopic Description in the New Era of Mucosal Healing
por: Rezapour, Mona, et al.
Publicado: (2019)

Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event
por: Berger, Joseph R., et al.
Publicado: (2018)

Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic
por: Dougados, Maxime
Publicado: (2021)

Role of Semaphorins in Immunopathologies and Rheumatic Diseases
por: Garcia, Samuel
Publicado: (2019)

Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey
por: Cherian, Somy, et al.
Publicado: (2021)

Nosocomial Transmission of SARS-CoV-2 Involving Vaccinated Health Care Workers
por: Pérez-Lago, Laura, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fmcthmqp2h6lkefc6fs1erpp62